Trial Profile
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary) ; Rosuvastatin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Biomarker; Pharmacodynamics
- Acronyms O-STAT Study
- 14 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 18 Jul 2022 Planned primary completion date changed from 31 May 2022 to 31 Dec 2022.
- 06 Dec 2021 Status changed from recruiting to active, no longer recruiting.